Stock LAB B GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genomma Lab Internacional, S.A.B. de C.V.

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
16.3 MXN +3.16% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +8.23% +15.11%
25/04 Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
24/04 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 11,007 18,932 19,061 21,614 16,849 15,150 15,150 -
Enterprise Value (EV) 1 15,465 24,043 23,381 26,264 21,719 17,681 17,116 17,621
P/E ratio 9.81 x 19.3 x 12.9 x 14.9 x - 13.1 x 7.41 x 7.5 x
Yield - - - 1.78% - 1.38% 0.95% 2.05%
Capitalization / Revenue 0.9 x 1.48 x 1.37 x 1.4 x 1 x 0.8 x 0.82 x 0.79 x
EV / Revenue 1.26 x 1.88 x 1.69 x 1.7 x 1.29 x 1.07 x 0.93 x 0.92 x
EV / EBITDA 6.13 x 9.35 x 7.97 x 8.18 x 6.26 x 5.12 x 4.17 x 4.08 x
EV / FCF 59.8 x 145 x 18 x 32.1 x 13.4 x 8.81 x 10.6 x 9.23 x
FCF Yield 1.67% 0.69% 5.55% 3.11% 7.49% 11.4% 9.44% 10.8%
Price to Book 1.64 x 2.38 x 2.05 x 1.96 x - 1.44 x 1.32 x 1.14 x
Nbr of stocks (in thousands) 9,43,145 10,11,839 10,11,744 10,06,240 9,94,639 9,29,461 9,29,461 -
Reference price 2 11.67 18.71 18.84 21.48 16.94 16.30 16.30 16.30
Announcement Date 26/02/19 26/02/20 24/02/21 23/02/22 22/02/23 21/02/24 - -
1MXN in Million2MXN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 12,282 12,756 13,867 15,460 16,859 16,467 18,365 19,185
EBITDA 1 2,522 2,571 2,932 3,210 3,471 3,454 4,109 4,322
EBIT 1 2,442 2,435 2,777 3,063 3,263 3,224 3,770 3,995
Operating Margin 19.88% 19.09% 20.03% 19.81% 19.35% 19.58% 20.53% 20.82%
Earnings before Tax (EBT) 1 1,915 1,536 2,247 2,313 2,261 1,685 2,946 3,429
Net income 1 1,218 986.7 1,478 1,451 1,397 1,031 2,305 2,244
Net margin 9.91% 7.74% 10.66% 9.39% 8.29% 6.26% 12.55% 11.7%
EPS 2 1.190 0.9700 1.460 1.440 - 1.080 2.200 2.173
Free Cash Flow 1 258.6 165.3 1,297 817.3 1,626 2,008 1,615 1,910
FCF margin 2.11% 1.3% 9.35% 5.29% 9.65% 12.19% 8.79% 9.96%
FCF Conversion (EBITDA) 10.26% 6.43% 44.23% 25.46% 46.86% 58.13% 39.3% 44.19%
FCF Conversion (Net income) 21.24% 16.75% 87.76% 56.33% 116.43% 194.81% 70.07% 85.11%
Dividend per Share 2 - - - 0.3817 - 0.1961 0.1554 0.3348
Announcement Date 26/02/19 26/02/20 24/02/21 23/02/22 22/02/23 21/02/24 - -
1MXN in Million2MXN
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3,865 3,984 4,063 4,015 4,324 4,349 4,171 4,178 4,370 4,393 3,525 3,644 - - -
EBITDA 1 776.5 819 889.9 826.6 892 912.4 839.9 867.3 920.1 933.7 732.3 755 - - -
EBIT 1 742 783.4 850.7 775.2 839.8 859.4 788.4 868.8 871.1 885.8 663.5 868.8 937.4 951.7 781.5
Operating Margin 19.2% 19.67% 20.94% 19.31% 19.42% 19.76% 18.9% 20.79% 19.93% 20.16% 18.82% 23.84% - - -
Earnings before Tax (EBT) 1 546.7 580.8 604.5 498.8 613.6 614.2 534.8 491.3 574.9 548.3 70.58 686.9 745.8 769.7 599.5
Net income 1 379.2 393.2 359.2 339.2 404.7 399.3 253.6 358 417.4 370.7 -115.5 342.7 492.2 508 395.7
Net margin 9.81% 9.87% 8.84% 8.45% 9.36% 9.18% 6.08% 8.57% 9.55% 8.44% -3.28% 9.4% - - -
EPS 2 0.3800 0.3900 0.3600 0.3400 0.4000 0.4000 - 0.3700 0.4300 0.3900 -0.1200 0.3575 0.4698 0.4874 0.4838
Dividend per Share - - 0.3817 - 0.3817 - - - 0.1961 0.1961 - - - - -
Announcement Date 28/07/21 27/10/21 23/02/22 27/04/22 27/07/22 26/10/22 22/02/23 26/04/23 26/07/23 25/10/23 21/02/24 - - - -
1MXN in Million2MXN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 4,459 5,112 4,320 4,650 4,870 4,520 1,966 2,471
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.768 x 1.988 x 1.473 x 1.449 x 1.403 x 1.309 x 0.4785 x 0.5717 x
Free Cash Flow 1 259 165 1,297 817 1,626 2,008 1,615 1,910
ROE (net income / shareholders' equity) 17% 12.6% 16.8% 14.1% 13.8% 10.6% 15.8% 15.5%
ROA (Net income/ Total Assets) 7.16% 5.28% 7.17% 6.51% 6.45% 4.88% 8.21% 9.71%
Assets 1 17,002 18,705 20,615 22,300 21,649 21,135 28,076 23,115
Book Value Per Share 2 7.100 7.870 9.200 11.00 - 9.830 12.40 14.30
Cash Flow per Share 2 1.100 0.9900 2.000 1.440 - 2.360 - -
Capex 1 868 839 726 630 402 247 546 602
Capex / Sales 7.06% 6.58% 5.23% 4.08% 2.38% 1.5% 2.97% 3.14%
Announcement Date 26/02/19 26/02/20 24/02/21 23/02/22 22/02/23 21/02/24 - -
1MXN in Million2MXN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genomma Lab Internacional, S.A.B. de C.V.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.3 MXN
Average target price
21.03 MXN
Spread / Average Target
+29.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. Stock Genomma Lab Internacional, S.A.B. de C.V.
+15.11% 882M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAB B Stock
  4. Financials Genomma Lab Internacional, S.A.B. de C.V.